Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Corticotropin, also known as adrenocorticotropic hormone (ACTH), is a 39-amino acid polypeptide hormone naturally produced by the anterior pituitary gland. It serves as a critical component of the hypothalamic-pituitary-adrenal (HPA) axis. Therapeutically, corticotropin is used to stimulate the adrenal cortex to secrete cortisol, corticosterone, and aldosterone. Its primary mechanism involves binding to the melanocortin 2 receptor (MC2R) in the adrenal gland, but it also interacts with other melanocortin receptors (MC1R, MC3R, MC4R, and MC5R) found on immune cells and other tissues, which may contribute to its direct anti-inflammatory and immunomodulatory properties. It is primarily indicated for the treatment of infantile spasms (West syndrome), acute exacerbations of multiple sclerosis, and various rheumatic, dermatologic, and allergic disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on corticotropin.